Levodopa News and Research

RSS

Impax announces positive top-line results of Phase III IPX066 study for Parkinson's disease

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced positive top-line results of the APEX-PD Phase III clinical study with IPX066 in Parkinson's disease (PD). IPX066 is a novel extended release carbidopa-levodopa product.

19 Nov 2010

Researcher hopes to provide effective medication for Parkinson's disease

The side effects of the standard medication for Parkinson's disease have long been a preoccupation of brain researchers. Now Daniella Rylander has presented new findings in a recently defended PhD thesis at Lund University that provide hope of more effective medication for those who suffer from the nerve cell disease.

21 Oct 2010

Michael J. Fox Foundation for Parkinson's Research announces awards totaling $10.1M

The Michael J. Fox Foundation for Parkinson's Research announced awards totaling approximately $10.1 million for five new clinical studies and 14 pre-clinical therapeutic development projects. The funding includes $2.5 million to drive four new clinical trials under the Clinical Intervention Awards, one of the Foundation's Edmond J. Safra Core Programs for PD Research.

6 Oct 2010

NeuroDerm receives $1M grant for development of ND0611 dermal patch for Parkinson's disease

NeuroDerm, Ltd. was informed today that it was awarded a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research. These funds will support the next clinical study with ND0611, a new dermal patch for the treatment of Parkinson's disease, as part of the Foundation's prestigious Clinical Intervention Awards 2010 program. This study will evaluate the safety, tolerability, levodopa pharmacokinetics, and possible clinical benefits of ND0611 in advanced Parkinson's disease patients.

6 Oct 2010

Watson seeks FDA approval to market rasagiline mesylate tablets

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rasagiline mesylate 0.5 and 1.0 mg tablets.

6 Oct 2010

USFDA grants Sun Pharma tentative approval for generic Stalevo ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Orion's Stalevo® tablets.

1 Oct 2010

NINDS establishes new sites as part of Morris K. Udall Centers of Excellence in Parkinson's Disease Research

The National Institute of Neurological Disorders and Stroke (NINDS), a component of the National Institutes of Health, has established two new sites as part of the Morris K. Udall Centers of Excellence in Parkinson's Disease Research. The NINDS grants will provide a five-year investment totaling more than $16 million for Emory University in Atlanta and the Feinstein Institute for Medical Research in Manhasset, N.Y.

29 Sep 2010

Higher education levels increases need for symptomatic control of Parkinson's disease

Individuals who have higher levels of education and who are more impaired by Parkinson's disease appear to require treatment for their symptoms earlier than do other patients, according to a report posted online today that will appear in the September print issue of Archives of Neurology, one of the JAMA/Archives journals.

28 Sep 2010

'Aspartame danger' myths

Heard the one about how aspartame single-handedly caused the Gulf War syndrome? In recent years, outlandish allegations – often spread via the Internet by individuals who have little scientific or medical expertise – have tried to link the low-calorie sweetener to every ailment ranging from Multiple Sclerosis and Parkinson's disease to cancer and weight gain. However, the overwhelming body of scientific evidence via more than three decades of research and over 200 studies demonstrate that aspartame is safe.

3 Sep 2010

Santhera, Ipsen partner to develop and commercialize fipamezole outside North America and Japan

Santhera Pharmaceuticals and Ipsen today announced a license agreement for the development and commercialization of fipamezole (antagonist of the adrenergic alpha-2 receptor) for territories outside of North America and Japan. This first-in-class compound is currently under investigation for the treatment of levodopa-induced dyskinesia in Parkinson's Disease.

3 Sep 2010

Impax Pharmaceuticals completes enrollment in IPX066 Phase III trial for Parkinson’s disease

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced that it has completed enrollment of its ADVANCE-PD trial. ADVANCE-PD is a multinational Phase III trial of its late-stage product IPX066 in advanced Parkinson's disease (PD) patients with motor fluctuations. IPX066 is an investigational extended release carbidopa-levodopa product intended to rapidly achieve and sustain effective blood concentrations of levodopa, potentially improving PD clinical symptom management.

26 Aug 2010

Placebo response in Parkinson's disease treatment varies with patient expectations

Individuals with Parkinson's disease were more likely to have a neurochemical response to a placebo medication if they were told they had higher odds of receiving an active drug, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Aug 2010

Parkinson's medication produces serious side effects in the form of involuntary, jerky movements: Research

One in every 100 elderly people suffers from Parkinson's disease, a disease of the nervous system with symptoms including stiffness and shaking. The standard medication used to treat Parkinson's is Levodopa, a drug that initially has major benefits but can later also produce serious side effects in the form of involuntary, jerky movements. A research group at Lund University has now found a way to study what it is in the brain that causes these side effects.

20 Jul 2010

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Of the three main types of oral drugs commonly added to levodopa therapy for patients with advanced Parkinson's disease, one might be the most effective, according to a new review.

9 Jul 2010

Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders

Chelsea Therapeutics International, Ltd. announced that data from its pivotal studies of Northera™ (droxidopa) in symptomatic neurogenic orthostatic hypotension was presented during a poster session and featured in a symposium highlighting the role of norepinephrine (NE) deficiency in Parkinson's disease at the 14th International Congress on Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina.

17 Jun 2010

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611. ND0611, a proprietary drug formula administered via a dermal patch, is designed to maintain continuous therapeutic levodopa concentrations for improving the treatment of Parkinson's disease.

1 Jun 2010

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has acquired the U.S. marketing rights to LODOSYN (carbidopa) tablets from Bristol-Myers Squibb Company.

26 Apr 2010

Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced that it has completed enrollment of its APEX-PD trial. APEX-PD is a multinational Phase III trial of its late-stage drug candidate IPX066 in subjects with early Parkinson's disease.

16 Apr 2010

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company's adenosine 2a receptor antagonist (SYN-115) in Parkinson's disease. The data demonstrate that SYN-115 significantly improves measures of motor and non-motor function in patients with Parkinson's disease either alone or in combination with levodopa.

15 Apr 2010

FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has approved once-daily Mirapex ER® (pramipexole dihydrochloride) extended-release tablets for the signs and symptoms of idiopathic Parkinson's disease, which includes early and advanced PD. PD is the second most common chronic neurological disorder in older adults after Alzheimer's. Parkinson's disease has no cure.

26 Mar 2010

Levodopa News and Research

Impax announces positive top-line results of Phase III IPX066 study for Parkinson's disease

Researcher hopes to provide effective medication for Parkinson's disease

Michael J. Fox Foundation for Parkinson's Research announces awards totaling $10.1M

NeuroDerm receives $1M grant for development of ND0611 dermal patch for Parkinson's disease

Watson seeks FDA approval to market rasagiline mesylate tablets

USFDA grants Sun Pharma tentative approval for generic Stalevo ANDA

NINDS establishes new sites as part of Morris K. Udall Centers of Excellence in Parkinson's Disease Research

Higher education levels increases need for symptomatic control of Parkinson's disease

'Aspartame danger' myths

Santhera, Ipsen partner to develop and commercialize fipamezole outside North America and Japan

Impax Pharmaceuticals completes enrollment in IPX066 Phase III trial for Parkinson’s disease

Placebo response in Parkinson's disease treatment varies with patient expectations

Parkinson's medication produces serious side effects in the form of involuntary, jerky movements: Research

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News